Announcements
- Annovis Announces New Publication in a Peer-Reviewed Journal
- Annovis Bio Provides Corporate Updates and Announces First Quarter 2024 Financial Results
- Annovis Announces Unblinding of the Buntanetap Phase III Data in Parkinson’s Disease
- Annovis Bio CEO Maria Maccecchini Issues Letter to Stockholders
- Annovis Bio Announces Statistically Significant Phase II/III Data in Patients With Early Alzheimer’s Disease
- Annovis Bio Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results
- Annovis Announces Publication That Supports Understanding of Buntanetap’s Mechanism of Action in Humans
- Annovis Bio Provides Data Announcement Update for the Phase II/III Study of Buntanetap in Alzheimer’s Disease
- Annovis Bio Announces Participation in Forum Discussion at AD/PD™ 2024
- Annovis Bio Announces Last Patient Last Visit in the Phase II/III Study of Buntanetap in Alzheimer’s Disease
More ▼
Key statistics
As of last trade, Annovis Bio Inc (07X:BER) traded at 6.20, 38.24% above the 52 week low of 4.49 set on May 09, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 6.24 |
---|---|
High | 6.41 |
Low | 6.07 |
Bid | 6.07 |
Offer | 6.37 |
Previous close | 6.23 |
Average volume | 610.56 |
---|---|
Shares outstanding | 11.17m |
Free float | 8.36m |
P/E (TTM) | -- |
Market cap | 73.17m USD |
EPS (TTM) | -5.04 USD |
Data delayed at least 15 minutes, as of Jun 04 2024 17:24 BST.
More ▼